VLA
Click for more information
0.00% $1.75 viralytics limited

what is merck doing with cavatac, page-3

  1. DavieJones
    222 Posts.
    lightbulb Created with Sketch. 9
    clock Created with Sketch.
    19/10/18
    11:01
    Post #: 36184788

    For those of us still following the progress of Cavatak, Merck is presenting the results of the KEYNOTE 200 trial at ESMO18 on the 20th Oct.


    LBA40 - Phase 1b KEYNOTE-200. A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

    Presentation Number LBA40

    Lecture Time17:15 - 17:15

    Speakers Charles M. Rudin (New York, US)


    http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=lba40



    Last edited by DavieJones: 19/10/18
    VLA Price at posting: $1.75 Sentiment: None Disclosure: Not Held
    Likes Created with Sketch. 1  Upvote
    lightbulb Created with Sketch.  Great analysis
    Stroke 3 Created with Sketch. Comments Created with Sketch. Reply

  2. Top Stories

 
watchlist Created with Sketch. Add VLA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.